Gabor Linthorst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gabor Linthorst has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ben Poorthuis
Academic Medical Centre, Amsterdam, Netherlands
1 shared publicationBouwien Smid
Academic Medical Centre, Amsterdam, Netherlands
1 shared publication- Brian W. Bigger
Centre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK
1 shared publication - Carla E. M. Hollak
Department of Endocrinology and Metabolism Amsterdam UMC, University of Amsterdam Amsterdam The Netherlands
1 shared publication Janneke Timmermans
UMC St. Radboud, Nijmegen, Netherlands
1 shared publication- Michael A. West
Aston University
1 shared publication
Latest Publications
- 1 September 2016
- Published by Oxford University Press (OUP)
Fabry Disease
Fabry disease was initially believed to be a very rare disorder, but an increase in prevalence following screening studies revealed that it may be more frequent in a less severe (nonclassical) variant. The adult physician can encounter both phenotypes: classical disease arising in childhood, or after establishing the diagnosis in an adult male. The nonclassical phenotype is usually diagnosed after additional investigations in a patient with renal disease or left ventricular hypertrophy (LVH) of unknown origin. Enzyme replacement therapy (ERT) appears to have a modest effect in Fabry disease, and many challenges remain both in understanding the pathophysiology and natural history as well as in improving patient outcomes.
- 1 September 2016
- Published by Oxford University Press (OUP)
Fabry Disease
Fabry disease was initially believed to be a very rare disorder, but an increase in prevalence following screening studies revealed that it may be more frequent in a less severe (nonclassical) variant. The adult physician can encounter both phenotypes: classical disease arising in childhood, or after establishing the diagnosis in an adult male. The nonclassical phenotype is usually diagnosed after additional investigations in a patient with renal disease or left ventricular hypertrophy (LVH) of unknown origin. Enzyme replacement therapy (ERT) appears to have a modest effect in Fabry disease, and many challenges remain both in understanding the pathophysiology and natural history as well as in improving patient outcomes.
- 1 March 2015
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (2) , 183-194
The role of antibodies in enzyme treatments and therapeutic strategies
- 1 March 2015
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (2) , 183-194
The role of antibodies in enzyme treatments and therapeutic strategies
- 1 February 2014
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 111 (2) , S98-S99
A case series study on diagnostic dilemmas in Fabry disease
- 1 February 2014
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 111 (2) , S98-S99
A case series study on diagnostic dilemmas in Fabry disease